Myocardial Infarction News and Research

RSS

Angion Biomedica initiates BB3 Phase II trial in heart attack

Angion Biomedica Corp. announced today that the first patient was dosed in a Phase II multicenter clinical trial evaluating BB3 for the treatment of heart attack (acute myocardial infarction).

19 Jul 2012

Childhood abuse affects the heart

Severe child abuse is a risk factor for cardiovascular disease in early adulthood, report researchers in Circulation.

18 Jul 2012

Adding stroke severity in hospital mortality model may improve prediction of death risk

Adding stroke severity to a hospital 30-day mortality model based on claims data for Medicare beneficiaries with acute ischemic stroke was associated with improvement in predicting the risk of death at 30 days and changes in performance ranking regarding mortality for a considerable proportion of hospitals, according to a study in the July 18 issue of JAMA.

18 Jul 2012

Heart-protective protein finally found

It is a cellular component so scarce, some scientists even doubted its existence, and many others gave up searching for its molecular structure. Now a team led by researchers at Johns Hopkins has defined the protein structural composition of mitoKATP, a potassium channel in the mitochondria of the heart and other organs that is known to protect against tissue damage due to a heart attack or stroke.

18 Jul 2012

Ticagrelor ‘now on equal footing’ with other antiplatelets

The platelet aggregation inhibitor ticagrelor is now considered of equal effectiveness to clopidogrel and prasugrel for patients who have experienced a heart attack or have unstable angina, a report states.

17 Jul 2012

Ticagrelor ‘now on equal footing’ with other antiplatelets

17 Jul 2012

AstraZeneca plans to conduct ticagrelor plus clopidogrel clinical trial for PAD

AstraZeneca today announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America.

17 Jul 2012

VHVI now offers new minimally invasive, catheter-based approach to dissolve pulmonary embolism

The Vanderbilt Heart and Vascular Institute (VHVI) now offers a minimally invasive, catheter-based approach to dissolving pulmonary embolism, a potentially life-threatening blood clot that form elsewhere in the body and travels into the lungs.

17 Jul 2012

InvivoSciences, WUSTL to construct artificial tissue models for heart failure

The National Institutes of Health has awarded more than $2 million to a team of scientists from Washington University in St. Louis and InvivoSciences, a biotechnology startup with WUSTL roots, to construct artificial tissue models that will allow the rapid testing of new drugs for heart failure.

17 Jul 2012

Prostate cancer treatment regrets linked to comorbidity

Men with cardiovascular disease are significantly more likely to regret their prostate cancer treatment choice than men without this comorbidity and have an increased risk for adverse effects, US researchers warn.

16 Jul 2012

NHS hospitals have scope to make efficiency savings by adopting best practice

NHS hospitals have substantial scope to improve their efficiency by adopting best practice, according to research published today by Professor Andrew Street and colleagues at the Centre for Health Economics (CHE) at the University of York.

14 Jul 2012

Disappointing result for acadesine

The adenosine-regulating agent acadesine does not reduce the occurrence of adverse outcomes in patients undergoing on-pump coronary artery bypass graft surgery, researchers say.

12 Jul 2012

Effective therapies to reduce perioperative morbidity and mortality remain elusive

Among intermediate- to high-risk patients undergoing coronary artery bypass graft surgery, administration of the agent acadesine to regulate adenosine (a naturally occurring chemical that dilates blood flow and can improve coronary blood flow and perfusion) did not reduce all-cause death, nonfatal stroke, or need for mechanical support for ventricular dysfunction, for approximately a month after surgery, according to a study in the July 11 issue of JAMA.

12 Jul 2012

BP variability link to stroke risk reinforced

Analysis of data from the Women’s Health Initiative supports the contention that variability in a person’s blood pressure affects their risk for stroke.

10 Jul 2012

Lessons learned from transfusion refusal

Jehovah’s Witness patients who refuse blood transfusions during cardiac surgery are not at risk for surgical complications or long-term mortality compared with non-Witnesses who receive transfusions, report US researchers.

10 Jul 2012

BP variability link to stroke risk reinforced

Analysis of data from the Women’s Health Initiative supports the contention that variability in a person’s blood pressure affects their risk for stroke.

10 Jul 2012

Peripheral arterial disease predicts mortality in TAVI patients

Patients with severe aortic stenosis who undergo transcatheter aortic valve implantation are at particularly high risk for complications and death if they also have concomitant peripheral arterial disease, study results show.

10 Jul 2012

COPD still affects treatment received after heart attack

Patients with chronic obstructive pulmonary disease receive less aggressive treatment after hospitalization for acute myocardial infarction than those without the lung condition, US study results show.

10 Jul 2012

Jehovah’s Witnesses’ beliefs do not necessarily put them at risk

Jehovah’s Witnesses do not have a significantly increased risk for complications or long-term mortality after cardiac surgery, researchers say.

10 Jul 2012

Treatment of Schizophrenia receives notice of intention to grant a European patent

BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received from the European Patent Office a notice of intention to grant a European patent claiming the salt of BL-1020, a first-in-class orally available treatment for schizophrenia.

9 Jul 2012